Decision tree-based modeling of androgen pathway genes and prostate cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 6, 2011, Pages 1146-1155

  Barnholtz Sloan, Jill S ^a   Guan, Xiaowei ^a   Zeigler Johnson, Charnita ^c   Meropol, Neal J ^a,b   Rebbeck, Timothy R ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR;

AFRICAN AMERICAN; ARTICLE; CANCER MODEL; CANCER RISK; CLASSIFICATION AND REGRESSION TREE; CONTROLLED STUDY; DECISION TREE; ETHNICITY; EUROPEAN AMERICAN; FAMILY HISTORY; GENE INTERACTION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; DECISION SUPPORT TECHNIQUES; DECISION TREES; DNA; HAPLOTYPES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPETITIVE SEQUENCES, NUCLEIC ACID; RISK FACTORS; ROC CURVE;

EID: 79958020615     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0996     Document Type: Article

References (54)

1. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
2. American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: American Cancer Society, Inc; 2010.
3. Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S, et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 2004;64:8461-7.
4. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-9. (Pubitemid 28407089)
5. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:928-32. (Pubitemid 37157963)
6. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:901-5. (Pubitemid 29508726)
7. McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010;141:210-7.
8. Nelen V. Epidemiology of prostate cancer. Recent Results Cancer Res 2007;175:1-8.
9. Williams H, Powell IJ. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol 2009;472:439-53.
10. Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev 1997;6:967-9. (Pubitemid 27481647)
11. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26. (Pubitemid 26274606)
12. Luke MC, Coffey DS. The male sex assessory tissues. Structure, androgen action and physiology. In: Knobil E, Neill JD, editors. The physiology of reproduction. 2nd ed. New York: Raven Press Ltd.; 1994. p. 1435-87.
13. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog 2003;37:202-8. (Pubitemid 36959536)
14. McIntyre MH, Kantoff PW, Stampfer MJ, Mucci LA, Parslow D, Li H, et al. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev 2007;16:2233-6.
15. Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K. Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer. PLoS One 2009;4:e6523.
16. Powell IJ. Prostate cancer in the African American: is this a different disease? Semin Urol Oncol 1998;16:221-6.
17. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444-9. (Pubitemid 46054044)
18. Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 1993;2:159-63. (Pubitemid 23075654)
19. Walker AH, Najarian D, White DL, Jaffe JF, Kanetsky PA, Rebbeck TR. Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ Health Perspect 1999;107:517-20. (Pubitemid 29371032)
20. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002;54:13-21. (Pubitemid 35404245)
21. Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF. A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet 2006;79:640-9. (Pubitemid 44452741)
22. Barnholtz-Sloan JS, McEvoy B, Shriver MD, Rebbeck TR. Ancestry estimation and correction for population stratification in molecular epidemiologic association studies. Cancer Epidemiol Biomarkers Prev 2008;17:471-7. (Pubitemid 351469194)
23. Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG. Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol Biomarkers Prev 2005;14:1545-51. (Pubitemid 40807360)
24. Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, et al. FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis 2010;31:1417-23.
25. SAS. Statistical analysis software, version 9.2. North Carolina:Cary; 2007.
26. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320-3. (Pubitemid 27157309)
27. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999;64:1371-7. (Pubitemid 30468755)
28. Schaid DJ. Evaluating associations of haplotypes with traits. Genet Epidemiol 2004;27:348-64. (Pubitemid 39602319)
29. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Boca Raton, FL: Chapman & Hall/CRC Press; 1984.
30. Pienta KJ, Goodson JA, Esper PS. Epidemiology of prostate cancer: molecular and environmental clues. Urology 1996;48:676-83. (Pubitemid 26398684)
31. Meikle AW, Smith JA Jr. Epidemiology of prostate cancer. Urol Clin North Am 1990;17:709-18. (Pubitemid 20371331)
32. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993;218:585-95. (Pubitemid 24003776)
33. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman- Sundberg M, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001;281:1349-55. (Pubitemid 32924568)
34. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91. (Pubitemid 32268418)
35. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002;30:1108-14.
36. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001;11:111-21. (Pubitemid 32216122)
37. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001;59:386-92. (Pubitemid 32108573)
38. Soderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F, et al. 5 alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002;12:307-12. (Pubitemid 34620658)
39. Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, et al. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate 2002;52:269-78.
40. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-9. (Pubitemid 21896702)
41. Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992;32:707-10.
42. Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev 2004;13:1765-71.
43. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70. (Pubitemid 27034793)
44. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000;60:5111-6.
45. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997;3:1599-608. (Pubitemid 27431569)
46. Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G. The 5 alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol 2005;48:679-85. (Pubitemid 41278596)
47. Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, Kawachi I, et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 1999;53:121-5. (Pubitemid 29016626)
48. Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF, et al. The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. Urol Int 2002;68:16-23. (Pubitemid 34102567)
49. Binnie MC, Alexander FE, Heald C, Habib FK. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate 2005;63:309-15. (Pubitemid 40664341)
50. Vijayalakshmi K, Thangaraj K, Rajender S, Vettriselvi V, Venkatesan P, Shroff S, et al. GGN repeat length and GGN/CAG haplotype variations in the androgen receptor gene and prostate cancer risk in south Indian men. J Hum Genet 2006;51:998-1005. (Pubitemid 44800746)
51. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 2002;155:478-84. (Pubitemid 34174160)
52. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:185-91.
53. Barry MJ. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 2009;360:1351-4.
54. Barry MJ. Review: evidence from 2 low quality screening studies does not show a reduction in death from prostate cancer. Evid Based Med 2007;12:40. (Pubitemid 46578862)